当前位置: X-MOL 学术Biotechnol. Bioeng. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs
Biotechnology and Bioengineering ( IF 3.5 ) Pub Date : 2021-09-29 , DOI: 10.1002/bit.27945
Carina C D Joe 1 , Jinlin Jiang 2 , Thomas Linke 2 , Yuanyuan Li 1 , Sofiya Fedosyuk 1 , Gaurav Gupta 1 , Adam Berg 1 , Rameswara R Segireddy 1 , David Mainwaring 3 , Amar Joshi 3 , Paul Cashen 3 , Byron Rees 3 , Nitin Chopra 4 , Piergiuseppe Nestola 5 , Jonathan Humphreys 6 , Sarah Davies 7 , Nick Smith 7 , Scott Bruce 7 , Dennis Verbart 8 , Daan Bormans 8 , Carol Knevelman 9 , Mark Woodyer 9 , Lee Davies 9 , Lisa Cooper 9 , Maria Kapanidou 9 , Nicole Bleckwenn 2 , Daniel Pappas 2 , Teresa Lambe 1 , Daniel C Smith 7 , Catherine M Green 10 , Raghavan Venkat 2 , Adam J Ritchie 1 , Sarah C Gilbert 1 , Richard Turner 11 , Alexander D Douglas 1
Affiliation  

Manufacturing has been the key factor limiting rollout of vaccination during the COVID-19 pandemic, requiring rapid development and large-scale implementation of novel manufacturing technologies. ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS-CoV-2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large-scale production. We discuss the process economics and the “distributed manufacturing” approach we have taken to provide the vaccine at globally-relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID-19 vaccine supply at low cost.

中文翻译:

制造黑猩猩腺病毒载体 SARS-CoV-2 疫苗以满足全球需求

在 COVID-19 大流行期间,制造一直是限制疫苗接种推广的关键因素,需要快速开发和大规模实施新型制造技术。ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) 是一种基于腺病毒载体的有效抗 SARS-CoV-2 疫苗。我们描述了基于同一平台生产这种疫苗和其他疫苗的过程的开发,包括促进超大规模生产的新功能。我们讨论了过程经济学和“分布式制造”方法,我们已经采用这种方法来提供全球相关规模的疫苗并确保国际供应安全。这些方法共同促成了迄今为止最大的病毒载体制造活动,以低成本提供了全球 COVID-19 疫苗供应的很大一部分。
更新日期:2021-12-04
down
wechat
bug